Interestingly, co-administration of anti-TGF-β agents along with anti-PD-L1 immunotherapeutic drugs successfully suppresses TGF-β signaling of CAFs, facilitating T cell infiltration in TME and enhancing anti-tumor immunity [139]. This evidence concerns the gene TGFB1 and neoplasm.